What it's for (Indications)
- Prednisolone, Neomycin, and Polymyxin B combination is typically indicated for the treatment of steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where superficial bacterial ocular infection or a risk of bacterial ocular infection exists.
- These conditions may include allergic conjunctivitis, anterior uveitis, keratitis, or other inflammatory states of the conjunctiva, cornea, and anterior segment of the globe.
- The corticosteroid component (prednisolone) is effective in reducing inflammation, redness, and swelling, while the antibiotic components (neomycin and polymyxin B) provide broad-spectrum coverage against susceptible Gram-positive and Gram-negative bacteria commonly implicated in ocular infections.
- For otic formulations, this combination is used for the treatment of superficial bacterial infections of the external auditory canal (otitis externa) and occasionally for specific types of otitis media with associated inflammation, provided there is no tympanic membrane perforation.
- Its use is justified when the benefits of an anti-inflammatory agent and two antibiotics are considered necessary.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | Dosage regimens for Prednisolone, Neomycin, and Polymyxin B vary significantly based on the specific formulation (e.g., ophthalmic drops, otic drops, ointment), the severity and nature of the condition being treated, and patient-specific factors. For ophthalmic use, a common regimen involves instilling one to two drops into the affected eye(s) multiple times daily, often starting with a higher frequency (e.g., every one to two hours) and gradually tapering as inflammation and infection subside. For otic use, typical administration involves instilling two to four drops into the affected ear(s) two to four times daily. The duration of treatment should generally be limited, usually not exceeding 7 to 10 days, to minimize the risks associated with prolonged corticosteroid use and potential antibiotic resistance. It is imperative to adhere strictly to the prescribing physician's instructions and the specific product's package insert for precise dosing, administration techniques, and duration of therapy. Self-medication or deviations from the prescribed regimen are strongly discouraged due to potential complications. |
Safety & Warnings
Common Side Effects
- Common side effects associated with ophthalmic or otic use of prednisolone, neomycin, and polymyxin B can include localized reactions such as transient stinging, burning, itching, or redness at the application site.
- For ophthalmic use, prolonged administration of the corticosteroid component may lead to significant adverse effects including elevation of intraocular pressure (IOP), which can progress to glaucoma with potential damage to the optic nerve, visual acuity defects, and formation of posterior subcapsular cataracts.
- Other ocular effects include delayed wound healing, thinning of the cornea or sclera leading to perforation, and increased susceptibility to secondary ocular infections (e.
- g.
- , fungal, viral, bacterial, including exacerbation of herpes simplex).
- Allergic sensitization, particularly to neomycin, can manifest as itching, redness, swelling of the conjunctiva, or eyelid edema.
- While systemic absorption is generally low with topical application, prolonged use or application to compromised barriers (e.
- g.
- , perforated tympanic membrane, extensive ocular surface damage) theoretically increases the risk of systemic adverse effects associated with neomycin (ototoxicity, nephrotoxicity) and polymyxin B (neurotoxicity, nephrotoxicity).
Serious Warnings
- Black Box Warning: SERIOUS WARNINGS: POTENTIAL FOR OTOTOXICITY AND NEPHROTOXICITY (NEOMYCIN/POLYMYXIN B) AND RISKS OF CORTICOSTEROID USE. While no formal FDA Black Box Warning exists for this specific combination topical product, due to the inherent risks associated with its active components, particularly under certain conditions, serious warnings are imperative. Topical application of neomycin and polymyxin B carries a theoretical, though rare with proper use, risk of systemic absorption which can lead to significant adverse effects associated with these antibiotics. Neomycin, an aminoglycoside, is well-known for its potential to cause irreversible ototoxicity (hearing loss and vestibular damage) and nephrotoxicity (kidney damage) when systemically absorbed. Polymyxin B can also cause neurotoxicity and nephrotoxicity upon systemic exposure. These risks are significantly heightened if the medication is applied to compromised epithelial barriers, such as a perforated tympanic membrane in otic use, or extensive abrasions or ulcerations in ocular use, allowing for increased systemic absorption. Therefore, this product is absolutely contraindicated in patients with a perforated tympanic membrane due to the direct and irreversible risk of ototoxicity. Patients should be carefully monitored for signs of ototoxicity or nephrotoxicity if there is any concern for significant systemic absorption, especially with prolonged use or in individuals with pre-existing renal impairment. Furthermore, prolonged use of the corticosteroid component, prednisolone, in the eye can lead to serious ocular complications including a sustained elevation of intraocular pressure (IOP) with possible development of glaucoma, optic nerve damage, and posterior subcapsular cataract formation. Corticosteroids can also mask, enhance, or exacerbate existing ocular infections (viral, fungal, bacterial) and retard corneal wound healing, potentially leading to perforation. These potential serious adverse effects necessitate careful patient selection, strict adherence to prescribed dosage and duration, and regular clinical monitoring during therapy.
- This combination product should be used with extreme caution.
- Prolonged use of corticosteroids in the eye may result in sustained elevation of intraocular pressure (IOP), potentially leading to glaucoma with damage to the optic nerve, defects in visual acuity and fields, and posterior subcapsular cataract formation.
- Regular monitoring of IOP is crucial for patients receiving ophthalmic corticosteroids for extended periods (typically beyond 10 days).
- The use of corticosteroids may also mask, enhance, or activate existing ocular or otic infections (herpes simplex, fungal, bacterial, viral).
- Fungal infections of the cornea are particularly prone to develop coincidentally with long-term corticosteroid applications; therefore, fungal invasion should be suspected in any persistent corneal ulceration where a corticosteroid has been used or is in use.
- Patients should be explicitly warned not to wear contact lenses during treatment with this product due to potential for absorption into the lens material, increased risk of infection, and ocular irritation.
- Topical corticosteroids may also delay corneal wound healing and can cause thinning of the cornea or sclera, which can lead to perforation in cases of pre-existing conditions that cause thinning.
How it Works (Mechanism of Action)
This combination product leverages the distinct pharmacological actions of its three active components to provide comprehensive treatment for inflammatory conditions with bacterial infection. Prednisolone is a potent synthetic corticosteroid that exerts its therapeutic effects by inhibiting the inflammatory response. It acts by inducing phospholipase A2 inhibitory proteins (lipocortins), which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes, thereby reducing swelling, redness, itching, and pain. Neomycin sulfate is an aminoglycoside antibiotic that inhibits bacterial protein synthesis by irreversibly binding to the 30S ribosomal subunit of susceptible bacteria, leading to the production of non-functional proteins and subsequent bacterial cell death. Polymyxin B sulfate is a cyclic polypeptide antibiotic that acts as a cationic detergent. It disrupts the integrity of the bacterial cell membrane in susceptible Gram-negative bacteria, particularly *Pseudomonas aeruginosa*, leading to leakage of intracellular components and rapid bacterial cell death. The synergistic action of these components provides broad-spectrum antibacterial coverage alongside powerful anti-inflammatory and anti-allergic effects, targeting both the infection and the associated inflammatory symptoms.
Commercial Brands (Alternatives)
No other brands found for this formula.